Profile data is unavailable for this security.
About the company
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.
- Revenue in USD (TTM)95.00k
- Net income in USD-327.27m
- Incorporated2017
- Employees232.00
- LocationAllogene Therapeutics Inc210 East Grand AvenueSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 457-2700
- Fax+1 (302) 636-5454
- Websitehttps://allogene.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma Corp | 18.14m | -72.85m | 484.67m | 73.00 | -- | 4.31 | -- | 26.72 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Avid Bioservices Inc | 136.74m | -17.96m | 486.89m | 365.00 | -- | 2.70 | -- | 3.56 | -0.284 | -0.284 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -3.97 | 10.73 | -6.03 | 15.22 | 7.47 | 22.72 | -13.13 | 25.92 | 0.3097 | -5.04 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
| Celcuity Inc | 0.00 | -63.78m | 496.39m | 55.00 | -- | 2.97 | -- | -- | -2.70 | -2.70 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -34.76 | -37.32 | -36.88 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2095 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 498.51m | 232.00 | -- | 0.9614 | -- | 5,247.49 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| ProKidney Corp | 0.00 | -35.47m | 500.47m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Altimmune Inc | 426.00k | -88.45m | 501.23m | 59.00 | -- | 2.57 | -- | 1,176.60 | -1.64 | -1.64 | 0.008 | 2.75 | 0.002 | -- | 0.6636 | 7,220.34 | -42.36 | -39.62 | -45.55 | -42.58 | -- | -- | -20,762.21 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| PetIQ Inc | 1.10bn | 2.13m | 501.29m | 1.93k | 274.89 | 2.24 | 10.21 | 0.4549 | 0.0614 | 0.0614 | 35.69 | 7.52 | 1.31 | 5.63 | 8.46 | 570,079.10 | 0.301 | -4.32 | 0.3777 | -5.23 | 22.94 | 20.05 | 0.2304 | -3.66 | 1.43 | 1.74 | 0.6671 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Verve Therapeutics Inc | 11.76m | -200.07m | 501.72m | 255.00 | -- | 0.8204 | -- | 42.67 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Applied Therapeutics Inc | 9.99m | -119.76m | 507.23m | 25.00 | -- | -- | -- | 50.76 | -1.42 | -1.42 | 0.1288 | -0.202 | 0.2145 | -- | -- | 399,720.00 | -257.01 | -140.37 | -- | -240.93 | -- | -- | -1,198.47 | -4,476.42 | -- | -- | -- | -- | -- | -- | -45.15 | -- | -- | -- |
| Alector Inc | 97.06m | -130.39m | 508.91m | 244.00 | -- | 3.34 | -- | 5.24 | -1.56 | -1.56 | 1.16 | 1.58 | 0.1377 | -- | 75.04 | 397,795.10 | -18.50 | -20.00 | -22.92 | -23.81 | -- | -- | -134.34 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 513.85m | 118.00 | -- | 4.76 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| Shattuck Labs Inc | 1.66m | -87.30m | 516.40m | 75.00 | -- | 3.55 | -- | 311.65 | -2.05 | -2.05 | 0.0389 | 3.06 | 0.0091 | -- | -- | 22,093.33 | -47.85 | -29.14 | -53.15 | -32.42 | -- | -- | -5,268.44 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 521.40m | 127.00 | -- | 6.57 | -- | 104.28 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -72.89m | 521.67m | 59.00 | -- | 2.64 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Humacyte Inc | 0.00 | -110.78m | 523.97m | 183.00 | -- | 33.68 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Allogene Therapeutics Inc's reporting currency: US Dollar USD
39.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 25.24m | 14.93% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 8.86m | 5.24% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 8.48m | 5.01% |
| PRIMECAP Management Co.as of 31 Dec 2023 | 5.28m | 3.12% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 3.88m | 2.29% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.87m | 2.29% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 2.98m | 1.77% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Dec 2023 | 2.74m | 1.62% |
| Woodline Partners LPas of 31 Dec 2023 | 2.58m | 1.52% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.43m | 1.44% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
